EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4 + lymphocytes

Elizabeth Hastie iD, Megha Srivasta, Edward R Cachay, Leah Burke, Sara Gianella, Stephen Rawlings, Frank Z Stanczyk, Craig Sykes, Angela D M Kashuba, Jill Blumenthal, Mackenzie L Cottrell

British Journal of Clinical Pharmacology · 2026-08 · 92 (8) · 2949-2959

DOI: 10.1002/bcp.70586 ↗

At a glance

Journal article in British Journal of Clinical Pharmacology, published online on 2026-05-07. Written by Elizabeth Hastie and 10 co-authors. Institution: University of California San Diego, San Diego, California, USA. Major MEDLINE topics: CD4-Positive T-Lymphocytes, Pre-Exposure Prophylaxis, HIV Infections, Transgender Persons. 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW). To address this gap, we examined drug metabolites in HIV susceptible cells isolated from blood and rectal tissues of TGW and CGW. Materials and Methods We enrolled 23 TGW, 13 on FHT and 10 CGW. Participants received five directly observed daily PrEP doses: emtricitabine 200 mg with either tenofovir disoproxil fumarate 300 mg (FTC/TDF) or tenofovir alafenamide 25 mg (FTC/TAF). Blood and rectal tissue samples were obtained. Mononuclear and CD4 + cells were isolated and analysed for intracellular triphosphorylated nucleotides (TFVdp and FTCtp) and total nucleotide pools (pTFV and pFTC) using HPLC‐MS/MS. Serum hormone concentrations were quantified via enzyme immunoassay. Results and Conclusion Total nucleotide pools (pTFV and pFTC) correlated with active metabolites (TFVdp and FTCtp) in blood and rectal CD4 + cells ( r 2 > 0.75, p < .001). No significant differences in pTFV or pFTC concentrations were observed between high and low oestradiol groups in either CGW or TGW ( p > .1). No correlation was observed between serum oestradiol concentrations and nucleotide concentrations. TAF resulted in 6.8‐fold higher median pTFV concentrations in blood CD4 + cells ( p < .001) but eightfold lower median pTFV concentrations in rectal CD4 + cells compared to TDF ( p = .008). These findings suggest that neither endogenous hormonal fluctuations in CGW nor exogenous FHT in TGW adversely impact intracellular PrEP pharmacology in key HIV target cells.

Subjects

MeSH terms (MEDLINE)

CD4-Positive T-LymphocytesPre-Exposure ProphylaxisHIV InfectionsTransgender PersonsAnti-HIV AgentsHumansFemaleAdultMaleRectumTenofovirMiddle AgedYoung AdultAlanineGonadal Steroid HormonesAdenineEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationNucleotides

Author keywords

HIVfeminizing hormone therapylower gastrointestinal tractpre‐exposure prophylaxistransgender

Substances

Anti-HIV AgentsTenofovirtenofovir alafenamideAlanineGonadal Steroid HormonesAdenineEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationNucleotides

Authors and institutions

  • University of California San Diego, San Diego, California, USA.
  • Mayo Clinic, Rochester, Minnesota, USA.
  • Maine Medical Center, Portland, Maine, USA.
  • University of Southern California, Los Angeles, California, USA.
  • University of North Carolina, Chapel Hill, North Carolina, USA.

ORCID profiles: Elizabeth Hastie

Funding

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Cite

APA

Hastie, E., Srivasta, M., Cachay, E. R., Burke, L., Gianella, S., Rawlings, S., Stanczyk, F. Z., Sykes, C., Kashuba, A. D. M., Blumenthal, J., & Cottrell, M. L. (2026). PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4 + lymphocytes. British Journal of Clinical Pharmacology, 92(8), 2949-2959. https://doi.org/10.1002/bcp.70586

Vancouver

Hastie E, Srivasta M, Cachay ER, Burke L, Gianella S, Rawlings S, et al. PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4 + lymphocytes. British Journal of Clinical Pharmacology. 2026;92(8):2949-2959. doi:10.1002/bcp.70586

BibTeX
@article{Hastie2026,
  author = {Hastie, Elizabeth and Srivasta, Megha and Cachay, Edward R and Burke, Leah and Gianella, Sara and Rawlings, Stephen and Stanczyk, Frank Z and Sykes, Craig and Kashuba, Angela D M and Blumenthal, Jill and Cottrell, Mackenzie L},
  title = {PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4 + lymphocytes},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  volume = {92},
  number = {8},
  pages = {2949--2959},
  doi = {10.1002/bcp.70586}
}
Start for free →